Sistema de Salut de Catalunya
Institut Català de la Salut
[Mora E] Hospital Universitario y Politécnico La Fe, Instituto de Investigación Sanitaria La Fe, Valencia, Spain. [Fox ML] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. HematologiaExperimental, Vall d’Hebron Institut d'Oncologia (VHIO), Barcelona, Spain. Departament de Medicina, Universidad Autònoma de Barcelona (UAB), Barcelona, Spain. [Lemes A] Department of Hematology, University Hospital of Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain. [Velasco B] Specialty Care Medical Department, GSK, Madrid, Spain. [Hernández-Rivas JM] Department of Medicine, University of Salamanca, Salamanca, Spain. Molecular Genetics in Oncohematology, Institute of Biomedical Research of Salamanca (IBSAL) - Cancer Research Center of Salamanca (USAL-CSIC), Salamanca, Spain
Vall d'Hebron Barcelona Hospital Campus
2026-04-01T12:56:03Z
2026-04-01T12:56:03Z
2025-11-14
Antibodies; Hypereosinophilic syndrome; Interleukin-5
Anticuerpos; Síndrome hipereosinofílico; Interleucina-5
Anticossos; Síndrome hipereosinofílica; Interleucina-5
Hypereosinophilic syndrome (HES) is a rare condition characterized by elevated eosinophil levels and related symptoms of eosinophil-mediated organ damage. We reviewed the effectiveness and safety of mepolizumab for the treatment of HES. A scoping review was conducted following the PRISMA Scoping Reviews Checklist to identify real-world evidence of mepolizumab use in HES. In total, 36 references were identified as relevant and selected for review. Overall, 105 patients previously treated with glucocorticoids received mepolizumab at different dosages (range: 100–750 mg), routes of administration (subcutaneous/intravenous), and schedules (every 2–12 weeks). Remission rates were 57.1–76.0%. Most studies reported a range of 71.4–99.1% reduction in mean blood eosinophil counts with mepolizumab treatment. In addition, a glucocorticoid-sparing effect was observed; 85.7% of patients discontinued glucocorticoids after 12 months of mepolizumab administration. Mepolizumab was considered safe and well-tolerated and severe adverse events were rare. Mepolizumab provided clinically significant benefits in patients with HES in a real-world setting.
The author(s) declare financial support was received for the research and/or publication of this article. This research was funded by GSK.
Article
Published version
Spanish
Avaluació de resultats (Assistència sanitària); Anticossos monoclonals - Ús terapèutic; Eosinofília; Sang - Malalties - Tractament; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome; DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Leukocyte Disorders::Eosinophilia::Hypereosinophilic Syndrome; Other subheadings::Other subheadings::Other subheadings::/drug therapy; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized; Other subheadings::Other subheadings::/therapeutic use; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento; ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::trastornos leucocitarios::eosinofilia::síndrome hipereosinofílico; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados; Otros calificadores::Otros calificadores::/uso terapéutico
Frontiers Media
Frontiers in Immunology;16
https://doi.org/10.3389/fimmu.2025.1704077
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3439]
